Literature DB >> 28439879

Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.

Ida Hude1,2, Stephanie Sasse1, Paul J Bröckelmann1, Bastian von Tresckow1, Jesko Momotow1, Andreas Engert1, Sven Borchmann1.   

Abstract

Entities:  

Keywords:  Hodgkin lymphoma; biomarkers; eosinophils; immune checkpoint inhibition; immunotherapy

Mesh：

Substances：

Year:  2017        PMID： 28439879     DOI： 10.1111/bjh.14705

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  11 in total

1.  Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.

Authors:  Paul J Bröckelmann; Helen Goergen; Ulrich Keller; Julia Meissner; Rainer Ordemann; Teresa V Halbsguth; Stephanie Sasse; Martin Sökler; Andrea Kerkhoff; Stephan Mathas; Andreas Hüttmann; Matthias Bormann; Andreas Zimmermann; Jasmin Mettler; Michael Fuchs; Bastian von Tresckow; Christian Baues; Andreas Rosenwald; Wolfram Klapper; Carsten Kobe; Peter Borchmann; Andreas Engert
Journal:  JAMA Oncol       Date:  2020-06-01       Impact factor: 31.777

2.  Absolute Increase in the Number and Proportion of Peripheral Eosinophils Associated With Immune Checkpoint Inhibitor Treatment in Non-small Cell Lung Cancer Patients.

Authors:  Hajime Osawa; Toshihiro Shiozawa; Shinichiro Okauchi; Yuika Sasatani; Gen Ohara; Shinya Sato; Kunihiko Miyazaki; Takahide Kodama; Katsunori Kagohashi; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Cancer Diagn Progn       Date:  2021-11-03

Review 3.  Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy.

Authors:  Sharon Grisaru-Tal; Marc E Rothenberg; Ariel Munitz
Journal:  Nat Immunol       Date:  2022-08-24       Impact factor: 31.250

4.  Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab.

Authors:  Nobuki Furubayashi; Akinori Minato; Takahito Negishi; Naotaka Sakamoto; Yoohyun Song; Yoshifumi Hori; Toshihisa Tomoda; Mirii Harada; Shingo Tamura; Akihiro Miura; Hiroki Komori; Kentaro Kuroiwa; Narihito Seki; Naohiro Fujimoto; Motonobu Nakamura
Journal:  Cancer Manag Res       Date:  2022-05-03       Impact factor: 3.602

5.  Detection of Specific Immune Cell Subpopulation Changes Associated with Systemic Immune Inflammation-Index Level in Germ Cell Tumors.

Authors:  Katarina Kalavska; Zuzana Sestakova; Andrea Mlcakova; Paulina Gronesova; Viera Miskovska; Katarina Rejlekova; Daniela Svetlovska; Zuzana Sycova-Mila; Jana Obertova; Patrik Palacka; Jozef Mardiak; Miroslav Chovanec; Michal Chovanec; Michal Mego
Journal:  Life (Basel)       Date:  2022-05-02

Review 6.  A new dawn for eosinophils in the tumour microenvironment.

Authors:  Sharon Grisaru-Tal; Michal Itan; Amy D Klion; Ariel Munitz
Journal:  Nat Rev Cancer       Date:  2020-07-16       Impact factor: 60.716

Review 7.  The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma.

Authors:  Nicholas Meti; Khashayar Esfahani; Nathalie A Johnson
Journal:  Cancers (Basel)       Date:  2018-06-15       Impact factor: 6.639

8.  Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.

Authors:  Quentin Scanvion; Johana Béné; Sophie Gautier; Aurélie Grandvuillemin; Christine Le Beller; Chouki Chenaf; Nicolas Etienne; Solenn Brousseau; Alexis B Cortot; Laurent Mortier; Delphine Staumont-Sallé; Franck Morschhauser; Alexandra Forestier; Matthieu Groh; David Launay; Eric Hachulla; Myriam Labalette; Jean-Emmanuel Kahn; Guillaume Lefèvre
Journal:  Oncoimmunology       Date:  2020-04-07       Impact factor: 8.110

9.  The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation.

Authors:  Margherita Rimini; Pierfrancesco Franco; Berardino De Bari; Maria Giulia Zampino; Stefano Vagge; Giovanni Luca Frassinetti; Francesca Arcadipane; Almalina Bacigalupo; Martina Valgiusti; Deborah Aloi; Lorenzo Gervaso; Renzo Corvò; Giulia Bartolini; Marianna Alessandra Gerardi; Stefano Cascinu; Andrea Casadei-Gardini
Journal:  Cancers (Basel)       Date:  2021-02-07       Impact factor: 6.639

10.  Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.

Authors:  Mario Scartozzi; Andrea Casadei-Gardini; Giulia Orsi; Francesco Tovoli; Vincenzo Dadduzio; Caterina Vivaldi; Oronzo Brunetti; Luca Ielasi; Fabio Conti; Giulia Rovesti; Laura Gramantieri; Mario Domenico Rizzato; Irene Pecora; Antonella Argentiero; Federica Teglia; Sara Lonardi; Francesca Salani; Alessandro Granito; Vittorina Zagonel; Giorgia Marisi; Giuseppe Cabibbo; Francesco Giuseppe Foschi; Francesca Benevento; Alessandro Cucchetti; Fabio Piscaglia; Stefano Cascinu
Journal:  Target Oncol       Date:  2020-12       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.